Two Biogen officials make the case for getting anti–tumor necrosis factor (TNF) biosimilars into wider play.
Anti—tumor necrosis factor (TNF) biosimilars can provide a more cost-effective, targeted approach to treatment of immune-mediated inflammatory diseases, according to a review paper.
“Along the course of the last 2 decades, TNF inhibitors, particularly etanercept, infliximab and adalimumab, have revolutionized the management of chronic immune-mediated inflammatory diseases; however, their relatively high cost prevented healthcare systems from exploiting their full clinical benefit,” Mourad F. Rezk, MD, global head of Medical Affairs for Biogen's biosimilars portfolio, and Burkhard Pieper, director of Scientific Affairs for Biogen, wrote in Advances in Therapy.
The wealth of real-world evidence on these agents suggests that not only is use increasing but also these drugs are improving access and outcomes, they explained.
“This includes the opportunity to realize clinical goals such as early initiation of biological treatment, treating to target, continuing treatment to maintain remission or low disease activity and reducing disease burden,” they wrote.
However, optimizing these biosimilars requires that biosimilars be approved “expeditiously,” competition against originator drugs is “optimized,” and patients are switched to biosimilars. “All of these actions will result in maximum cost savings, which can then be reinvested into patient care,” they wrote.
Biogen turned in a good second-quarter 2020 financial performance, with modestly improved earnings; however, biosimilar revenues declined 7%.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Switching Patterns Highlight Nocebo Effect in European Patients Using Amgevita
July 23rd 2024About half of the patients in a European study who transitioned from reference adalimumab to a biosimilar version stayed on the biosimilar at the 1-year mark. However, researchers warned about a possible nocebo effect resulting in some patients switching back to the originator.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.